Xpand Biotechnology is a biotech company that specializes in the development of novel therapies for a range of diseases. The company is based in Israel and was founded in 2018 by a team of experienced biotech entrepreneurs and researchers.
Xpand Biotechnology’s research focuses on the discovery and development of small molecule drugs that can modulate the activity of key proteins involved in disease pathways. The company’s drug discovery platform uses a combination of computational modeling, high-throughput screening, and in vitro and in vivo testing to identify promising drug candidates.
One of the main areas of focus for Xpand Biotechnology is the development of new treatments for cancer. The company is developing a pipeline of small molecule drugs that target specific signaling pathways involved in cancer growth and metastasis. These drugs have the potential to be more effective and have fewer side effects than traditional chemotherapy drugs.
In addition to cancer research, Xpand Biotechnology is also involved in the development of therapeutics for other diseases, such as autoimmune disorders and viral infections. The company is developing small molecule drugs that target specific protein-protein interactions that are involved in the development and progression of these diseases.
Xpand Biotechnology has established partnerships with a number of academic institutions and biotech companies to advance its research and development efforts. For example, the company has partnered with the Weizmann Institute of Science to develop new treatments for multiple sclerosis, and with the biotech company Enlivex Therapeutics to develop therapies for sepsis and cytokine storm syndrome.
Overall, Xpand Biotechnology is a promising biotech company that is focused on the development of novel therapies for a range of diseases. With its strong research and development capabilities, and its partnerships with leading academic and industry partners, the company is well-positioned to make important contributions to the biotech industry in the coming years.